Alligator’s clinical leadership transition plan
Swedish firm Alligator Bioscience (STO: ATORX) hasannounced that Dr Sumeet Ambarkhane, chief medical officer, will be leaving the company by end of March 2025, noting that he has played a key role in advancing Alligator’s immune-oncology pipeline and establishing its clinical development organization over the past years.
In particular, he led the clinical development of mitazalimab and OPTIMIZE-1, Alligator’s Phase II trial in metastatic pancreatic cancer towards its readiness for a Phase III confirmatory development. The company extends its sincere gratitude for his contributions and wishes him success in his future endeavors.
Having worked with the company for an extended period, enabling a smooth transition, Dr Tom Moore will assume the role as chief medical officer. He will assume his role from the start of April ensuring a smooth transition in Alligator’s clinical development leadership.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze